Refine by
Clinical Phases Technology
19 companies found
Technologybased inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
Technologybased inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Technologybased inYongin-si, SOUTH KOREA
Vivozon is a global innovative drug development company established in 2008. We built an efficacy-based new drug discovery system that is clearly distinct from the existing new drug development paradigm, and discovered the non- narcotic analgesic ...
As atreatment for postoperative pain used as a first-line therapy in the global market, Opiranserin aims to ultimately replaceopioid analgesics by providing an effective and safe solution for pain management. With the hope to combat opioidmisuse and ...
Technologybased inDaejeon, SOUTH KOREA
We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...
DearDTI presents drug candidates with a good efficacy by predicting the binding affinity, based on information about the compound-protein ...
Technologybased inSan Diego, CALIFORNIA (USA)
Evofem Biosciences is revolutionizing women’s sexual and reproductive healthcare with a first-in-class innovative hormone-free contraceptive and STI prevention compound in development. Evofem’s mission is to empower women by providing products that ...
EVO100 (the investigational name for Phexxi) is in development for two potential new indications, the prevention of urogenital chlamydia and urogenital gonorrhea in women, leveraging its vaginal pH modulator mechanism of action. Infection with these ...
Technologybased inGeneve, SWITZERLAND
STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have ...
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches ...
Technologybased inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
Technologybased inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging is a clinical phase biotechnology company focused on enabling image guided interventional medicine. The company´s molecular targetting technology has the potential to tackle disease in real-time to allow interventional ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a ...
Technologybased inVictoria, AUSTRALIA
The Scinogy team is dedicated to making your clinical results a commercial reality. Provide optimized solutions for the development and manufacture of high quality, affordable cell therapies. Choosing manufacturing technologies and a scale-up ...
Technologybased inWhite Plains, NEW YORK (USA)
Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy ...
Technologybased inRye Brook, NEW YORK (USA)
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is ...
The U.S. Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are ...
Technologybased inNes-Ziona, ISRAEL
Kadimastem is a bio-pharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. ...
We Have Reached Successful Pre-clinical results of our cell Therapy Treatment for Insulin-Dependent Diabetes. Diabetes mellitus is a chronic disorder characterized by high blood glucose levels and glucose intolerance, due to insulin deficiency, ...
Technologybased inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
Technologybased inPessac, FRANCE
We bring together biophysicists, stem cell biologists & bioproduction engineers around the motto 'Cell Therapy for All'. TreeFrog Therapeutics was created to provide access to safe, efficient and affordable cell therapies for millions of patients. ...
C-Stem™ is a biomimetic cell culture technology allowing for the mass-production of stem cell- derived therapies with unprecedented cell quality, while cutting manufacturing costs by 10x. ...
Technologybased inParis, FRANCE
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and ...
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the ...
Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
Technologybased inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
Oncodesign’s Pharmimage® technology module is a pharmaco-imaging module designed to monitor the effect of treatments and to define effective translational biomarkers in precision medicine. It includes translational, optical ...
Technologybased inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...